Vivoryon Therapeutics
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG0079ZD8K3
VVY
Vivoryon Therapeutics
GICS: -
·
Sector: Clinical trials
·
Sub-Sector: -
NAME
Vivoryon Therapeutics
ISIN
NL00150002Q7
TICKER
VVY
MIC
XAMS
REUTERS
VVY.AS
BLOOMBERG
VVY NA
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
In this section you will find transaction histories for short sales.
ai
NALIZER
Short sellers are obliged to report when building up positions from 0.50% and when reducing positions up to 0.50%. If there are open positions >= 0.50% in the reporting registers, these are shown in the following overview.
One Short sale positions >= 0.50% are currently registered as reportable-relevant
| Date | Position Holder | Position | # | Action |
|---|---|---|---|---|
| 13.01.2025 | Citadel Securities (Europe) Limited | 0,60% | 19 |
The overview shows all positions and their last reported status. Please note that when reducing positions, falling below the 0.50% limit means that the mandatory reporting obligations no longer have to be applied. As a rule, it can be assumed that the positions have been completely reduced following a longer period of inactivity. Positions < 0.50% are therefore only of limited significance.
| Date | Position Holder | Position | # | Action |
|---|---|---|---|---|
| 13.01.2025 | Citadel Securities (Europe) Limited | 0,60% | 19 | |
| 16.09.2024 | Voleon Capital Management LP | 0,49% | 13 | |
| 21.06.2024 | Millennium International Management LP | 0,45% | 18 | |
| 28.05.2024 | GSA Capital Partners LLP | 0,47% | 6 | |
| 05.03.2024 | Janus Henderson Investors UK Limited | 0,00% | 279 | |
| 04.03.2024 | Adage Capital Management L.P. | 0,00% | 6 |
Information on product placements
The information provided in this area is compiled with care and prepared and processed in complex technical process steps. Quality assurance is an integral part of the methods and procedures used. A plausibility check is carried out to the extent that the source data allows. Before further use, especially in the course of any investment decisions, we recommend consulting at least one second independent source for validation.
SMART * AD
P R O D U C T S U G G E S T I O N S
